Cancer Supportive Care Drugs Market To Reach $12.17 Billion By 2030

Cancer Supportive Care Drugs Market Growth & Trends

The global cancer supportive care drugs market size is expected to reach USD 12.17 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to decline at a CAGR of -1.26% from 2023 to 2030. This decline is due to factors, such as the launch of biosimilar and approval & uptake of targeted treatments for cancer, which have lesser side effects than traditional chemotherapy drugs. The growing cancer prevalence, high adoption & dependency on traditional treatments, such as chemotherapy, in the developing region, and the rising geriatric population are some of the prominent factors that drive the market growth. According to Globocan, the number of new cancer cases is expected to reach 28.4 million within the next two decades, with a rise of 47% from 2020.

In addition, in developing regions, such as Asian and African countries, due to less disposable income levels and lack of proper reimbursement scenarios, chemotherapy is the most widely preferred cancer treatment compared to other costly targeted therapies. However, the growing adoption of targeted therapies and biosimilars in Europe and the U.S. impedes the market growth. The patent expiration of blockbuster drugs, such as Amgen Inc.’s Neupogen and Neulasta and Johnson & Johnson Services, Inc.’s Procrit/Eprex, is another factor that hampers the market growth. Furthermore, the COVID-19 pandemic has had a significant impact on cancer care. There was a substantial decline in hospital visits, cancer screenings, surgeries, and therapy amid the pandemic.

However, the impact of the pandemic has declined and conditions are getting back to normal in many regions from the second quarter of 2021. Key players are addressing the opportunity of drug patient expiration and thus, are launching biosimilars in the market. The launch of biosimilars has supported expanded access to affordable care for cancer patients. For instance, in June 2020, Pfizer Inc. received the U.S. FDA approval for NYVEPRIA (pegfilgrastim-apgf), a biosimilar to Neulasta. It reduces the incidence of febrile neutropenia in patients with non-myeloid malignancies undergoing myelosuppressive anticancer medications. In November 2019, Novartis AG received the FDA approval for Ziextenzo, its biosimilar version of pegfilgrastim. The product was commercialized in Europe in 2018.

 Request a free sample copy or view report summary: Cancer Supportive Care Drugs Market Report

Cancer Supportive Care Drugs Market Report Highlights

• The G-CSFs (Granulocyte-colony Stimulating Factors) segment accounted for the highest share in 2022. It is a primary treatment option for cancer-related neutropenia

• The antiemetics segment is expected to show positive growth during the forecast period due to the launch of newer drugs, such as Cinvanti, Sustol, and Varubi

• North America and other developed regional markets are expected to decline over the forecast period

• The declining sales in developed markets can be attributed to the launch & rapid uptake of multiple biosimilar & restrictions on opioid prescription

Cancer Supportive Care Drugs Market Segmentation

Grand View Research has segmented the global cancer supportive care drugs market based on therapeutic class and region:

Cancer Supportive Care Drugs Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)

• G-CSFs (Granulocyte-colony Stimulating Factors)

• ESAs (Erythropoiesis Stimulating Agents)

• Anti-emetics

• Bisphosphonates

• Opioids

• NSAIDs & Others

Cancer Supportive Care Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • U.K.

  • Germany

  • Spain

  • France

  • Italy

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • UAE

  • Saudi Arabia

  • Kuwait

List of Key Players of Cancer Supportive Care Drugs Market

• Amgen, Inc

• Merck & Co., Inc.

• Johnson & Johnson Services, Inc.

• Heron Therapeutics, Inc.

• Novartis AG

• GlaxoSmithKline plc (GSK)

• F. Hoffmann-La Roche Ltd.

• Helsinn Healthcare SA